Implications of the Inflation Reduction Act for cancer medicine development
The Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program (MDPNP) directs the Secretary of Health and Human Services (HHS) to set a maximum...
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
Follow us on LinkedIn: CRA on Rare Disease
We are rare disease specialists.
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
- 50+Rare disease areas covered
- 500+Rare disease engagements since 2019
Our rare disease offerings span across the product lifecycle.
- Early developmentDiscover
- Pipeline opportunity assessment
- Diagnostics & screening
- Early Pricing Marketing Access (PMA)
- Licensing / commercially reasonable efforts disputes
- Late developmentDevelop
- Market access & evidence generation strategy
- Payer value proposition
- Patient finding
- Landscape assessment & policy shaping
- LaunchDeliver
- Launch pricing strategy
- Payer negotiation
- Launch excellence
- Stakeholder engagement
- Competitive simulations
- Uptake and diffusion
- Life cycle & LOEDefend
- Indication & geographic expansion
- Competitor response strategies
- Price/access/uptake benchmarking and assessments
- LOE strategies
Engagements
- 01Evaluating the potential impact of cross-border healthcare for gene therapiesCRA's Rare Disease team evaluated the dynamics of cross-border healthcare using secondary research to explore current precedence and/or previous product...View engagement
- 02Global pricing and access strategic issues assessment for rare diseases gene therapy portfolioCRA delivered recommendations on optimization and risk mitigation for gene therapy pricing strategy implementation...View engagement
- 03Understanding and segmenting a rare disease marketOur client sought to develop a better understanding of the market for a rare disease, including patient diversity and treatment, in anticipation of...View engagement
Contact a Rare Disease expert.
See all Rare Disease expertsRecent and Upcoming Events
ISPOR The Global Socioeconomic Impact of Rare Diseases: A Call for Action Webinar
CRA’s Clara Zacharko will be presenting a CRA study on an ISPOR webinar titled “The Global Socioeconomic Impact of Rare Diseases: A Call for Action” on May...
Asembia: AXS24 Summit
CRA is exhibiting at the conference at booth #2018. Matt Majewski presents his session titled “What is a Fair Price for a Rare Disease Therapy?”...